<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908217</url>
  </required_header>
  <id_info>
    <org_study_id>SEMAPHORE (RB15.210)</org_study_id>
    <nct_id>NCT02908217</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE</brief_title>
  <official_title>Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Chugai</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients are treated with infusions of Tocilizumab (TCZ) or placebo for 5 months. Clinical
      evaluation is performed using PMR-AS.

      The PMR-AS is computed by summing the 5 variables after multiplying by 0.1 for weighting
      purposes: PMR-AS (activity scale = AS) = C reactive protein (CRP) (mg/dl) + patient scale
      (VASp) (0-10 scale) + physician scale (VASph) (0-10 scale) + morning stiffness(MST)
      [min]×0.1) + elevation of upper limbs (EUL) (0-3 scale).

      All the patients included are treated with glucocorticoid (GC).GC are reduced at each visit
      until the end of the study, depending on response to treatment and PMR-AS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low disease activity (PMR-AS&lt;10) with steroid independence (GCs ≤5 mg absolute value) or decrease ≥ 10 mg from week 0 to week 24).</measure>
    <time_frame>From week 0 to week 24</time_frame>
    <description>PMR-AS measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with (PMR-AS&gt;17) in both arm</measure>
    <time_frame>From Week 24 to Week 32</time_frame>
    <description>PMR-AS measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PMR-AS and proportion of patients with PMR-AS &lt; 1.5; 10; 17.</measure>
    <time_frame>From inclusion to week 32</time_frame>
    <description>PMR-AS measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dosages of GCs at Week 32</measure>
    <time_frame>Week 32</time_frame>
    <description>dosages of GCs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Polymyalgia Rheumatica</condition>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 Intravenous infusions of placebo (sterile sodium chloride solution) every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.</description>
    <arm_group_label>Tocilizumab</arm_group_label>
    <other_name>Intravenous infusions of tocilizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6 Intravenous infusions of placebo every 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Intravenous infusions of placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age older than 50 years

          -  Fulfilled the Chuang criteria

          -  And currently:

               -  PMR-AS&gt; 10

               -  Absence of signs or symptoms of other musculoskeletal or connective tissue
                  conditions

          -  Able to give informed consent

          -  Concomitant treatments with methotrexate or hydroxy-chloroquine are permitted if
             stable dose since 3 months.

        Exclusion Criteria:

          -  Clinical symptoms of giant cell arteritis

          -  Uncontrolled dyslipidemia, high blood pressure or cardiovascular disease

          -  History of major organ or haematopoietic stem cell/marrow transplant

          -  Clinical evidence of significant unstable or uncontrolled acute or chronic diseases
             not due to PMR

          -  Planned surgical procedure within 12 months after randomization.

          -  History of malignant neoplasm within the last 5 years.

          -  Current active infection

          -  Patient with elevated ALT or AST&gt; 5 ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Devauchelle-Pensec, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valérie Devauchelle-Pensec, Pr</last_name>
    <phone>0033 2 98 34 72 64</phone>
    <email>valerie.devauchelle-pensec@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Nord service de rhumatologie-Franche Comté</name>
      <address>
        <city>Belfort</city>
        <zip>90000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>anne LOHSE</last_name>
    </contact>
    <contact_backup>
      <email>Anne.LOHSE@hnfc.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CIC Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Toussirot, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Eric Toussirot, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Wendling, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Wendling, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Richez, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Richez, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Devauchelle-Pensec</last_name>
    </contact>
    <investigator>
      <last_name>Valérie Devauchelle-Pensec, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain Saraux, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Sud-Francilien</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal HILLIQUIN</last_name>
    </contact>
    <contact_backup>
      <email>Pascal.Hilliquin@ch-sud-francilien.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard BONNOTTE</last_name>
    </contact>
    <contact_backup>
      <email>bernard.bonnotte@chu-dijon.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle Dernis, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuelle Dernis, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital européen</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent CHICHE</last_name>
    </contact>
    <contact_backup>
      <email>l.chiche@hopital-europeen.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ch Des Pays de Morlaix</name>
      <address>
        <city>Morlaix</city>
        <zip>29600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>catherine LE HENAFF</last_name>
    </contact>
    <contact_backup>
      <phone>0033298626041</phone>
      <email>CLehenaff@ch-morlaix.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CH Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre KIEFFER</last_name>
    </contact>
    <contact_backup>
      <email>kiefferp@ghrmsa.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marie Berthelot, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Marie Berthelot, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>hôpital Sapêtrière -APHP</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno-Jean FAUTREL, Pr</last_name>
    </contact>
    <contact_backup>
      <email>bruno.fautrel@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleth Perdriger, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Aleth Perdriger, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU St Etienne</name>
      <address>
        <city>St Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hubert MAROTTE</last_name>
    </contact>
    <contact_backup>
      <email>hubert.marotte@chu-st-etienne.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Eric GOTTENBERG</last_name>
    </contact>
    <contact_backup>
      <email>jacques-eric.gottenberg@chru-strasbourg.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polymyalgia Rheumatica</keyword>
  <keyword>Tocilizumab</keyword>
  <keyword>Glucocorticoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

